Investigational Drug Information for Idasanutlin
✉ Email this page to a colleague
What is the development status for investigational drug Idasanutlin?
Idasanutlin is an investigational drug.
There have been 15 clinical trials for Idasanutlin.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 30th 2015.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Hoffmann-La Roche, National Center for Tumor Diseases, Heidelberg, and University Hospital Heidelberg.
There are twenty-seven US patents protecting this investigational drug and three hundred international patents.
Summary for Idasanutlin
| US Patents | 27 |
| International Patents | 300 |
| US Patent Applications | 249 |
| WIPO Patent Applications | 159 |
| Japanese Patent Applications | 23 |
| Clinical Trial Progress | Phase 1 (2015-12-30) |
| Vendors | 48 |
Recent Clinical Trials for Idasanutlin
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors | St. Jude Children's Research Hospital | Phase 1 |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Hoffmann-La Roche | Phase 2 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Le | Hoffmann-La Roche | Phase 1/Phase 2 |
Clinical Trial Summary for Idasanutlin
Top disease conditions for Idasanutlin
Top clinical trial sponsors for Idasanutlin
US Patents for Idasanutlin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Idasanutlin | ⤷ Sign Up | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Sign Up |
| Idasanutlin | ⤷ Sign Up | Compounds targeting proteins, compositions, methods, and uses thereof | Biotheryx, Inc. (Chappaqua, NY) | ⤷ Sign Up |
| Idasanutlin | ⤷ Sign Up | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids | Cantex Pharmaceuticals, Inc. (Weston, FL) | ⤷ Sign Up |
| Idasanutlin | ⤷ Sign Up | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Sign Up |
| Idasanutlin | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Idasanutlin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Idasanutlin | Australia | AU2015211021 | 2034-01-28 | ⤷ Sign Up |
| Idasanutlin | Australia | AU2020244600 | 2034-01-28 | ⤷ Sign Up |
| Idasanutlin | Australia | AU2022256167 | 2034-01-28 | ⤷ Sign Up |
| Idasanutlin | Brazil | BR112016017564 | 2034-01-28 | ⤷ Sign Up |
| Idasanutlin | Canada | CA2939121 | 2034-01-28 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
